📄 medicine

Prognostic Analysis of Iodine-avid Residual Metastatic Lymph Nodes in Differentiated Thyroid Cancer

This study demonstrates that in differentiated thyroid cancer patients with iodine-avid residual metastatic lymph nodes, the number and size of these nodes alongside stimulated thyroglobulin levels are independent predictors of persistent radioactive iodine uptake, enabling the development of a nomogram to forecast functional therapeutic response.

Original authors: Ruoxin Xu, Qingyuan Jia, Mingxuan Zhao, Qiyong Pan, Caihua Tang

Published 2026-10-14

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Ruoxin Xu, Qingyuan Jia, Mingxuan Zhao, Qiyong Pan, Caihua Tang

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Thyroid cancer, specifically the most common type known as differentiated thyroid cancer, is a disease where the body's thyroid gland grows abnormal cells that usually grow slowly. Because these cells often behave like healthy thyroid tissue, they have a unique ability to absorb iodine, a mineral found in salt and seafood. Doctors use this trait to treat the disease. After surgically removing the thyroid gland, patients may take a dose of radioactive iodine. This radioactive material travels through the bloodstream and is absorbed by any remaining thyroid cells or cancer cells that have spread to other parts of the body, such as the lymph nodes in the neck. The radiation then destroys these cells from the inside. While this treatment is highly effective for many people, it does not work the same way for everyone. Even when patients receive the same amount of radioactive iodine, some see their cancer disappear completely, while others continue to show signs of active disease on follow-up scans. Understanding why this happens is crucial for deciding how to monitor patients and whether they need further treatment.

Researchers at The Fifth Affiliated Hospital of Sun Yat-Sen University set out to solve this puzzle by looking closely at patients who had cancer that had spread to their lymph nodes and was clearly visible on a special scan taken after their first dose of radioactive iodine. They studied 220 patients who had undergone surgery and then received this initial treatment. The team examined the images from the scans, which act like a map showing exactly where the radioactive iodine had settled, along with blood test results taken before the treatment. They were particularly interested in the physical characteristics of the cancer spots in the lymph nodes: how many spots there were, how big they were, and whether they contained calcium deposits. They also looked at a specific blood marker called stimulated thyroglobulin, which acts as a signal indicating how much thyroid tissue or cancer remains in the body.

The study revealed that for the majority of these patients, the treatment worked well. After the initial dose, nearly 87 percent of the patients showed no sign of radioactive iodine uptake in their lymph nodes during follow-up scans, meaning the cancer cells in those areas had been successfully cleared. However, about 13 percent of the patients still had active spots that continued to absorb the radioactive iodine, suggesting the cancer persisted in those specific nodes. The researchers compared the two groups to find out what made the difference. They discovered that patients whose cancer remained active had higher levels of the blood marker before treatment, a greater number of cancer spots in their lymph nodes, and larger individual spots compared to those who were cured. Interestingly, the size of the spots and the number of spots were the most reliable indicators when looking at the images alone.

One of the most significant findings was that the amount of radioactive iodine given did not determine the outcome. Patients who still had active cancer had actually received higher doses of the treatment than those who were cured. This suggests that the persistence of the disease was not because the dose was too low, but because the underlying disease was more extensive or aggressive to begin with. The researchers also found that the brightness of the spots on the scan, which indicates how much iodine the cancer was absorbing, did not predict whether the treatment would work. A spot that glowed brightly did not necessarily mean it would disappear, nor did a dim spot mean it would stay. This finding challenges the idea that simply seeing how much iodine a tumor takes up is enough to predict the result.

To help doctors predict the future for patients with similar conditions, the team built a new tool called a nomogram. This is a visual chart that combines three specific pieces of information: the level of the blood marker before treatment, the total number of cancer spots in the lymph nodes, and the size of the largest spot. By plugging these three numbers into the chart, a doctor can estimate the likelihood that a patient will have persistent cancer after treatment. The tool was tested on the group of patients in the study and showed a good ability to distinguish between those who would be cured and those who would not. The researchers noted that while the tool is promising, it was developed from a single hospital's data and needs to be tested on larger groups of people in different places before it can be used widely.

The study concludes that for patients with thyroid cancer that has spread to the lymph nodes, the first dose of radioactive iodine is often successful. However, the success depends heavily on the burden of the disease, specifically how many spots are present and how large they are, rather than just the intensity of the treatment given. By using the blood marker and a careful count and measurement of the cancer spots on the scan, doctors can now better predict which patients might need closer monitoring or additional therapy. This approach moves away from a one-size-fits-all strategy and toward a more personalized plan based on the specific details of the cancer found in each individual patient.

Technical Summary: Prognostic Analysis of Iodine-avid Residual Metastatic Lymph Nodes in Differentiated Thyroid Cancer

Problem Statement
While Differentiated Thyroid Cancer (DTC) generally carries a favorable prognosis, cervical lymph node metastasis and postoperative residual disease remain significant causes of persistent disease and structural recurrence. Although Radioiodine ( $^{131}$ I) therapy is standard for remnant ablation and treating known disease, clinical outcomes are heterogeneous. Even among patients with equivalent TNM stages, recurrence risk categories, or administered $^{131}$ I activities, the response to initial therapy varies substantially. Specifically, some patients achieve complete resolution of iodine uptake in metastatic lymph nodes, while others exhibit persistent uptake or the emergence of new iodine-avid lesions. Current risk stratification based on clinicopathological features alone is often insufficient for precise individualized management. Furthermore, while post-therapy whole-body scans with SPECT/CT (Rx-WBS) can identify iodine-avid residual metastatic lymph nodes (reLNs), previous studies have rarely integrated quantitative uptake characteristics and morphological features (such as nodal number, size, and calcification) to predict functional treatment response.

Methodology
This retrospective study analyzed 220 postoperative DTC patients who underwent initial $^{131}$ I therapy and presented with iodine-avid reLNs on Rx-WBS at The Fifth Affiliated Hospital of Sun Yat-sen University between September 2020 and January 2024.

Data Collection: Clinical variables included age, sex, tumor characteristics, AJCC 8th TNM stage, ATA risk stratification, pre-therapy stimulated thyroglobulin (ps-Tg), and administered $^{131}$ I activity.
Imaging Analysis: On initial Rx-WBS, researchers recorded the number of reLNs, maximum short-axis diameter (on axial CT), presence of calcification, regional involvement, and semiquantitative iodine uptake indices (lymph node-to-mediastinal blood pool ratio and lymph node-to-contralateral soft-tissue ratio).
Response Evaluation:
1. Overall Response: Assessed via 2015 ATA criteria (Excellent, Indeterminate, Biochemical Incomplete, Structural Incomplete).
2. Functional Response: Defined specifically by the persistence or disappearance of iodine uptake in metastatic lymph nodes on follow-up scans. Patients were stratified into an "iodine uptake disappearance" group and a "persistent iodine uptake" group.
Statistical Modeling: Univariable and multivariable logistic regression were used to identify independent predictors of persistent uptake. A nomogram was constructed and internally validated using bootstrap resampling (500 repetitions) to assess discrimination (AUC, C-index) and calibration. Decision Curve Analysis (DCA) was performed to evaluate clinical utility.

Key Results

Therapeutic Outcomes: Following initial $^{131}$ I therapy, 44.5% of patients achieved an Excellent Response (ER), and 74.5% achieved an acceptable response (ER + Indeterminate Response). In terms of functional outcomes, 86.8% of patients showed complete resolution of radioactive iodine uptake in metastatic lymph nodes, while 13.2% exhibited persistent uptake.
Predictive Factors: Patients in the persistent uptake group had significantly higher administered $^{131}$ I activity, higher ps-Tg levels, a greater number of iodine-avid lymph nodes, larger maximum short-axis diameters, and a higher frequency of calcification compared to the disappearance group.
Multivariable Analysis:
- Combined Model: Pre-therapy ps-Tg ( $P=0.020$ ) and the number of iodine-avid lymph nodes ( $P=0.039$ ) were identified as independent predictors of persistent iodine uptake.
- Imaging-Only Model: When excluding biochemical markers, the number of lymph nodes and maximum short-axis diameter remained independent predictors. Semiquantitative uptake ratios (mediastinal or contralateral) were not significant independent predictors.
Model Performance: The constructed nomogram, incorporating ps-Tg, nodal number, and maximum short-axis diameter, achieved an Area Under the Curve (AUC) of 0.792 (95% CI, 0.678–0.906). Calibration curves showed good agreement between predicted and observed probabilities, and DCA indicated the model provided a net benefit over "treat all" or "treat none" strategies across a threshold probability range of 0.10–0.90.

Significance and Claims
The authors claim that initial $^{131}$ I therapy yields favorable outcomes for DTC patients with iodine-avid reLNs, with the majority achieving functional resolution of uptake. The study highlights that persistent iodine uptake is closely related to tumor burden, specifically reflected by pre-therapy ps-Tg levels and the morphological characteristics of the metastatic nodes (number and size).

The primary contribution of this work is the development of a novel nomogram that integrates biochemical (ps-Tg) and imaging (nodal number and size) features to preliminarily achieve individualized prediction of functional therapeutic response. The authors posit that this tool can assist clinicians in identifying patients at higher risk of poor functional response, thereby supporting risk-stratified surveillance strategies and individualized follow-up or retreatment decisions.

The paper acknowledges limitations, including its retrospective nature, the relatively small sample size of the persistent uptake group, the focus solely on iodine-avid nodes, and the lack of external validation. Consequently, the authors modestly frame the nomogram as a preliminary tool requiring future multicenter, prospective validation before widespread clinical implementation.

Technical Summary: Prognostic Analysis of Iodine-avid Residual Metastatic Lymph Nodes in Differentiated Thyroid Cancer

More like this